Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$27.60
+2.7%
$28.34
$23.23
$42.29
$886.84M0.76443,114 shs250,977 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$18.65
-1.4%
$19.31
$13.30
$30.03
$913.93M1.03263,269 shs216,047 shs
Epizyme, Inc. stock logo
EPZM
Epizyme
$1.47
$1.47
$0.41
$5.80
$247.44M-0.413.23 million shs7,960 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.40
-0.7%
$1.63
$1.15
$2.04
$940.17M1.783.89 million shs2.72 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+0.30%-0.15%-9.56%-17.98%-26.22%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
+3.84%+16.58%-10.25%-10.12%+10.07%
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00%0.00%0.00%0.00%0.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%+2.92%-17.06%-6.00%+11.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.0476 of 5 stars
3.41.00.03.02.80.82.5
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.2554 of 5 stars
3.60.00.00.02.84.20.0
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.4911 of 5 stars
3.43.00.04.42.15.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.80
Moderate Buy$43.6057.97% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.25
Buy$40.33116.26% Upside
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00
N/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.7596.43% Upside

Current Analyst Ratings Breakdown

Latest EPZM, OPK, ELVN, and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
4/7/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/24/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
3/21/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$37.00 ➝ $39.00
3/19/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
3/3/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
2/28/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
2/4/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$37.00 ➝ $36.00
(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.40$10.00 per share2.76$5.99 per share4.61
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$5.97 per shareN/A
Epizyme, Inc. stock logo
EPZM
Epizyme
$37.43M6.61N/AN/A($0.54) per share-2.72
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.14M1.32N/AN/A$1.80 per share0.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$48.15M$1.8611.904.58N/A14.78%104.67%18.38%5/8/2025 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)
Epizyme, Inc. stock logo
EPZM
Epizyme
-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$188.86M-$0.09N/AN/AN/A-18.65%-9.76%-6.46%4/30/2025 (Estimated)

Latest EPZM, OPK, ELVN, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.51N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50N/AN/AN/A$174.96 millionN/A
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07N/AN/AN/A$163.13 millionN/A
3/13/2025Q4 2024
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.53-$0.46+$0.07-$0.46N/A$0.03 million
2/27/2025Q4 2024
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.54$1.63+$0.09$0.36$179.68 million$181.95 million
2/27/2025Q4 2024
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.08$0.01+$0.09$0.01$155.42 million$183.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.43
0.97
0.88
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
17.44
17.44
Epizyme, Inc. stock logo
EPZM
Epizyme
N/A
5.35
5.19
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.30
2.97
2.69

Institutional Ownership

CompanyInstitutional Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Epizyme, Inc. stock logo
EPZM
Epizyme
76.45%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.51%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
29.20%
Epizyme, Inc. stock logo
EPZM
Epizyme
23.40%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million30.97 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5049.00 million34.59 millionOptionable
Epizyme, Inc. stock logo
EPZM
Epizyme
250168.33 million128.97 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
4,200671.55 million359.94 millionOptionable

Recent News About These Companies

Analyst Expectations For OPKO Health's Future
Opko Health initiated with a Neutral at JPMorgan

New MarketBeat Followers Over Time

Media Sentiment Over Time

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$27.60 +0.73 (+2.72%)
Closing price 04:00 PM Eastern
Extended Trading
$27.61 +0.01 (+0.04%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$18.65 -0.26 (-1.37%)
Closing price 04:00 PM Eastern
Extended Trading
$18.64 -0.01 (-0.05%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Epizyme stock logo

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.40 -0.01 (-0.71%)
Closing price 04:00 PM Eastern
Extended Trading
$1.40 0.00 (-0.29%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.